We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Advanced Cell Technology, a US pharmaceutical company, has been granted beneficial "orphan drug" status under the Orphan Drug Act by the US Food and Drug Administration for an embryonic stem cell therapy which it is developing to treat Stargardt's Macular Dystrophy, a rare form of blindness
